Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
Abstract: rtN236V mutants from patient 1 and patient 2 exhibited 3.90-fold and 3.10-fold decreased susceptibility to ADV, respectively, compared to the wild-type virus; by contrast, rtN236T mutants from the patients had 4.50-fold and 4.75-fold decreased susceptibility, respectively.
Abstract: RESULTS: rtN236V was detected in six ADV-refractory patients; signature ADV-resistant mutations rtA181V and rtN236T were detected in 1,311 patients.
Novel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma.
Result: It is worth noting that we did not observe any of the common NA-related resistance mutations including rtM204V/I, rtS202C/G/I, rtL180M, rtA181T/V, rtT184A/I/L/G/C/M, rtA194T, rtI169T, rtV173L, rtL80I, rtN236T, and PMID: 24835494
2014
PloS one
Result: The N236T adefovir dipivoxil resistance mutation and other previously described resistance mutations against other antiviral drugs (e.g.
Discussion: Besides other previously described resistance mutations, the best-described drug resistance mutations are the LAM resistance mutations rtL180M and rtM204V/I and the adefovir resistance mutations rtA181V/T and rtN236T.
Discussion: Other antiviral therapy resistance mutations, such as rtA181V/T or rtN236T, were not detected.
Sensitivity of drug-resistant mutants of hepatitis B virus to poly-IC.
Abstract: Compared to the wt virus, the capacity of virus replication was reduced in most LAMr and ETVr mutants except those with mutations rtM(204V+L180M+V173L), and was similary in the ADVr mutants except rt(A121V+N236T).
Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates.
PMID: 25493022
2014
World journal of gastroenterology
Abstract: Patients with the rtA181T mutant were primarily infected with genotype C and e-antigen negative HBV, while patients with the rtN236T mutant were primarily infected by genotype B HBV (chi(2) = 6.004, 7.159; P = 0.023, 0.007).
Abstract: The most prevalent mutations were rtA181T, rtV214A, and rtN236T.
Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Abstract: Subsequently, wild type was replaced by the rtN236T and/or rtA181V/T mutant.
Abstract: The rtN236T mutation was not observed in any clone.
Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility.
PMID: 25028473
2014
The Journal of general virology
Abstract: Replication-competent HBV constructs containing rtI187V and combined with LAM-resistant (rtM204I, rtL180M/rtM204V) mutations were generated, and compared with WT, LAM-resistant single (rtM204I) or double (rtL180M/rtM204V) and ADV-resistant (rtN236T) clones.
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
PMID: 25061278
2014
Drug design, development and therapy
Conclusion: Further, there were no substitutions that could be associated with reduced TDF susceptibility (rtA181V/T, rtN236T, or rtA194T) in April 2013.
Discussion: For these 45 patients, which included ten with virologic breakthrough, both line probe assay and direct sequencing revealed no new amino acid substitutions, including substitutions that could be associated with reduced TDF susceptibility (rtA181V/T, rtN236T, or rtA194T).
Discussion: It has been shown that rtA181V +
Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance.
Abstract: Major mutational patterns conferring nucleoside/nucleotide analog resistance include the combinations rtL180M/rtM204(I/V) (for lamivudine, entecavir, telbivudine and clevudine) and rtA181V/rtN236T (for adefovir and tenofovir).
Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study.
Result: rtV173L, rtL180M, rtA181V/T, rtT184G, rtS202I, rtM204V/I, rtN236T and rtM250V were first studied and then, others residues with changes present in at least two patients were further considered.
HBV mutation literature information.
PMID: 
2014
Antiviral therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT